Cerenis Therapeutics is a multinational Biopharma company, dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) known as reverse cholesterol transport, represent the next frontier in the treatment of cardiovascular disease. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001) to fight atherosclerosis.